The Biomembrane Institute

University of Washington

Oncomembrane, Inc.

Fred Hutchinson Cancer Center

Sloan-kettering Institute for Cancer Research

Otsuka America Pharmaceutical, Inc.

Hyogo Medical College

Sen-Itiroh Hakomori

Yasuyuki Igarashi

Edward D Nudelman

Henrik Clausen

Anil Singhal

Shigeyuki Kawa

Yoshito Sadahira

Mark R Stroud

Steven B Levery

Tatsushi Toyokuni

Helio K Takahashi

Fuqiang Ruan

Thomas J Kjeldsen

Cho-chou Kuo

Hidemitsu Matsuura

Noriko Takahashi

Walter E Stamm

Ann Stapleton

Fugiang Ruan

Albertina F Swanson

M Jules Mattes

Kazuko Handa

Junichi Sakamoto

Hirofumi Okoshi

Mary Ellen Salyan

Koichi Furukawa

Mohammad N Ahmad

Hisao Nojiri

Katherine Look

Ulla Mandel-Clausen

Hanrik Clausen

Yoshiyuki Tsuji

Shinzo Isojima

Mary Ellen Salvan

Satoshi Kimura

Koiti Titani

Khalid K Sadozai

Yong S Park

Nobuo Hanai

Gustavo A Nores

Taeko Dohi

Lloyd Kenneth O

Tokio Kaizu

Oligosaccharides specific formediate attachment of the organism to host cells.

Chlamydia oligosaccharides

[object Object]

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.

Method for determining susceptibility to Escherichia coli urinary tract

The invention relates to trimethylsphingosine derivatives which have some or all of the activities of the parent compound.

Trimethylsphingosine derivatives

A method of inhibiting tumor cell chemotactic motility and/or chemoinvasion, a method of inhibiting phagokinetic activity of tumor cells and neutrophils, a method of inhibiting tumor cell metastasis and a method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising contacting the cells or administering to a host in need of treatment an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives is also described.

Method for inhibition of cell motility by sphingosine-1-phosphate and

A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.

Monoclonal antibodies and vaccine development directed to human

A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising administering to a host in need of treatment an inflammation inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives.

Sphingosine-1-phosphate essentially free of L-threo isomer

A vaccine and method to prevent growth and replication of cancer cells that express a core structure of a mucin-type glycoprotein is disclosed. The vaccine comprises: (a) a pharmaceutically effective amount of an antigen comprising a purified mucin-type glycoprotein or a chemically synthesized mucin-type glycoprotein carbohydrate determinant conjugated to a carrier peptide or macromolecule, wherein said mucin-type glycoprotein expresses or carries the core structure of a mucin-type glycoprotein expressed on said cancer cells; and (b) a pharmaceutically acceptable carrier including natural or synthetic adjuvants. The method comprises administering the above-described vaccine to a host. A medicament and method for treating cancer wherein the cancer cells express a core structure of a mucin-type glycoprotein is disclosed. The medicament comprises: (a) a pharmaceutically effective amount of an anti-cancer antibody or fragment comprising a binding site thereof, said anti-cancer antibody having been produced against a purified core structure of a mucin-type glycoprotein; and (b) a pharmaceutically acceptable carrier, diluent or excipient. The method comprises administering the above-described medicament to a host.

Sphingosine-1-phosphate/N,N,N-trimethylsphingosine composition to modulate cell growth.

Sphingosine-1-phosphate/trimethylsphingosine composition

N-methylated sphingosine used to induce apoptosis.

Methylsphingosine used to treat apoptosis

The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.

Methods for the production of antibodies and induction of immune

A process for preparing difucosyl Y.sub.2 antigen (dimeric Le.sup.x) , said process comprising: (1) preparing a lactonorhexaosylceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the III.sup.3 and V.sup.3 positions through an .alpha.1.fwdarw.3 linkage. A process for preparing Le.sup.y antigen analogues, said process comprising: (1) preparing a lactonorhexaosyl-ceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the terminal .beta.-Gal through an .alpha.1.fwdarw.2 linkage; and (3) enzymatically fucosylating said backbone at one or more positions through an .alpha.1.fwdarw.3 linkage, provided that steps (2) and (3) can be conducted simultaneously or in any order. A process for preparing a fucosylated lactonorhexaosylceramide, lactonorhexaosylsaccharide linked to a carrier molecule or higher analogues thereof, said process comprising: (1) preparing a lactonorhexaosylceramide backbone, a lactonorhexaosylsaccharide backbone linked to a carrier molecule or backbones of higher analogues thereof; and (2) enzymatically fucosylating one or more residues of said backbone. A process for preparing sialyl Le.sup.x and sialyl dimeric Le.sup.x.

Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3

Method for inhibition of cell motility by sphingosine-1-phosphate, its

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue are disclosed.

Method for determining susceptibility to escherichia coli urinary tract

Growing community of inventors

Seattle, WA, United States of America

Sen-Itiroh Hakomori